FDA 483 - In2Bones, SAS - October 27, 2016

An FDA inspection of In2Bones, SAS, a device manufacturer in Ecully, France, identified one observation related to quality system deficiencies. The firm's procedures for supplier control were found to be inadequately defined, specifically regarding follow-up actions based on supplier evaluations. This indicates a moderate severity issue concerning quality management system oversight.